Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 20 01:26PM ET
1.09
Dollar change
-0.03
Percentage change
-2.68
%
IndexRUT P/E- EPS (ttm)-2.45 Insider Own14.44% Shs Outstand87.75M Perf Week-14.84%
Market Cap96.51M Forward P/E- EPS next Y-0.72 Insider Trans0.00% Shs Float75.76M Perf Month-23.78%
Income-214.44M PEG- EPS next Q-0.33 Inst Own79.80% Short Float6.65% Perf Quarter-16.79%
Sales0.00M P/S- EPS this Y28.45% Inst Trans63.92% Short Ratio10.90 Perf Half Y-62.15%
Book/sh1.17 P/B0.93 EPS next Y52.82% ROA-81.27% Short Interest5.04M Perf Year-76.76%
Cash/sh1.57 P/C0.69 EPS next 5Y26.70% ROE-111.56% 52W Range0.98 - 5.64 Perf YTD-60.07%
Dividend Est.- P/FCF- EPS past 5Y0.51% ROI-151.67% 52W High-80.67% Beta0.87
Dividend TTM- Quick Ratio4.11 Sales past 5Y0.00% Gross Margin- 52W Low11.24% ATR (14)0.09
Dividend Ex-Date- Current Ratio4.11 EPS Y/Y TTM-1.12% Oper. Margin0.00% RSI (14)39.66 Volatility5.90% 8.11%
Employees131 Debt/Eq0.39 Sales Y/Y TTM- Profit Margin- Recom2.50 Target Price2.90
Option/ShortYes / Yes LT Debt/Eq0.36 EPS Q/Q-63.58% Payout- Rel Volume0.85 Prev Close1.12
Sales Surprise- EPS Surprise-83.22% Sales Q/Q- EarningsMay 09 AMC Avg Volume462.10K Price1.09
SMA20-13.25% SMA50-9.00% SMA200-38.30% Trades Volume246,820 Change-2.68%
Date Action Analyst Rating Change Price Target Change
Jan-17-24Downgrade Jefferies Buy → Hold $6 → $1.50
Jan-16-24Downgrade Cantor Fitzgerald Overweight → Neutral
Dec-18-23Upgrade William Blair Mkt Perform → Outperform
Dec-08-23Resumed Jefferies Buy $9 → $6
Sep-27-23Initiated JMP Securities Mkt Outperform $11
May-12-23Upgrade Jefferies Hold → Buy $6 → $9
Mar-07-23Initiated Piper Sandler Overweight $22
Sep-12-22Downgrade SMBC Nikko Neutral → Underperform $2
Dec-22-21Downgrade William Blair Outperform → Mkt Perform
Dec-22-21Downgrade SVB Leerink Outperform → Mkt Perform $17
May-28-24 07:02AM
May-10-24 04:02PM
May-09-24 10:56PM
04:02PM
May-03-24 07:31AM
06:31AM Loading…
Apr-09-24 06:31AM
Apr-04-24 08:36AM
Mar-16-24 05:31AM
Mar-14-24 09:54PM
04:02PM
Feb-26-24 07:02AM
Feb-12-24 07:02AM
Jan-18-24 09:35AM
Jan-17-24 12:10PM
Jan-16-24 11:36AM
09:40AM Loading…
09:40AM
09:28AM
07:27AM
07:17AM
07:02AM
07:00AM
05:09AM
Nov-13-23 05:01PM
04:02PM
Sep-27-23 12:10PM
Aug-30-23 04:05PM
Aug-09-23 04:02PM
Aug-02-23 04:05PM
08:20AM
Jun-12-23 07:02AM
07:02AM Loading…
Jun-05-23 07:02AM
May-13-23 08:05AM
May-12-23 05:00PM
May-09-23 04:02PM
Mar-07-23 04:05PM
Mar-06-23 04:02PM
Jan-26-23 05:33AM
Dec-15-22 11:35AM
Dec-09-22 12:00PM
Nov-29-22 07:02AM
Nov-10-22 09:02AM
Nov-07-22 04:05PM
Oct-14-22 06:35PM
Sep-30-22 11:48AM
Sep-24-22 08:32AM
Sep-19-22 07:00AM
Sep-12-22 07:02AM
Sep-09-22 08:47AM
07:00AM
Aug-31-22 02:10PM
Aug-04-22 04:04PM
Jul-25-22 04:05PM
Jul-08-22 10:18AM
May-06-22 04:05PM
Apr-28-22 06:00PM
Apr-19-22 06:15PM
Apr-12-22 06:15PM
Apr-09-22 10:03AM
Mar-28-22 06:15PM
Mar-22-22 06:15PM
Mar-15-22 06:00PM
Mar-07-22 10:39AM
Mar-03-22 11:05AM
Mar-01-22 04:05PM
Feb-25-22 06:00PM
Feb-21-22 09:53AM
Feb-17-22 02:38AM
Feb-08-22 01:38PM
Feb-07-22 01:38PM
Feb-04-22 06:00PM
Feb-01-22 01:38PM
08:00AM
Jan-24-22 06:15PM
01:53PM
Jan-12-22 12:09PM
Jan-09-22 06:26AM
Jan-06-22 08:17AM
Jan-05-22 06:59AM
Jan-04-22 10:00AM
09:40AM
Dec-22-21 04:37PM
12:36PM
10:41AM
09:07AM
Dec-21-21 07:15PM
Dec-20-21 08:32AM
Dec-08-21 07:38PM
07:38PM
Nov-30-21 07:00AM
Nov-19-21 10:27AM
08:40AM
Nov-08-21 04:05PM
Oct-25-21 08:00AM
Oct-24-21 03:35PM
Sep-30-21 11:12AM
08:39AM
Sep-29-21 08:47AM
Aug-09-21 04:01PM
Jul-29-21 05:31PM
Jul-21-21 06:44AM
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.